株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ワルデンシュトレームマクログロブリン血症 : パイプライン分析

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 213065
出版日 ページ情報 英文 199 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
ワルデンシュトレームマクログロブリン血症 : パイプライン分析 Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016
出版日: 2016年10月12日 ページ情報: 英文 199 Pages
概要

ワルデンシュトレームマクログロブリン血症(WM)とは、マクログロブリンと呼ばれる異常なタンパク質が大量に作られる非ホジキンリンパ腫(NHL)の一種で、年齢、性別、家族歴、C型肝炎、特定の自己免疫疾患などがリスクファクターとしてあります。特にシェーグレン症候群などは特に高いリスクがあります。治療には、幹細胞移植、生物学的治療、化学療法、放射線治療などがあります。

当レポートでは、世界におけるワルデンシュトレームマクログロブリン血症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

ワルデンシュトレームマクログロブリン血症の概要

治療薬の開発

  • ワルデンシュトレームマクログロブリン血症向けパイプライン製品:概要
  • ワルデンシュトレームマクログロブリン血症向けパイプライン製品:比較分析

ワルデンシュトレームマクログロブリン血症:開発中の治療薬:企業別

ワルデンシュトレームマクログロブリン血症:開発中の治療薬:大学・研究機関別

ワルデンシュトレームマクログロブリン血症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ワルデンシュトレームマクログロブリン血症:開発中の製品:企業別

ワルデンシュトレームマクログロブリン血症:開発中の製品:大学・研究機関別

ワルデンシュトレームマクログロブリン血症:治療薬開発に従事している企業

  • AbbVie Inc.
  • arGEN-X BV
  • Bayer AG
  • BeiGene(Beijing) Co.,Ltd
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Idera Pharmaceuticals, Inc.
  • IGF Oncology, LLC.
  • Incyte Corporation
  • Karyopharm Therapeutics, Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Onyx Pharmaceuticals, Inc.

ワルデンシュトレームマクログロブリン血症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (INCB-039110+INCB-040093)
  • 765IGF-MTX
  • acalabrutinib
  • ARGX-110
  • BGB-3111
  • カーフィルゾミブ
  • CB-839
  • copanlisib hydrochloride
  • DI-B4
  • entospletinib
  • エベロリムス
  • FV-162
  • FV-214
  • HMPL-523
  • idelalisib
  • IMO-8400
  • INCB-39110
  • INCB-40093
  • INCB-50465
  • ixazomib citrate
  • lenalidomide
  • オファツムマブ
  • oprozomib
  • pevonedistat hydrochloride
  • selinexor
  • 免疫学・腫瘍学向け IRAK4 阻害小分子
  • spebrutinib besylate
  • venetoclax
    • 製品概要
    • 作用機序
    • R&Dの進捗

ワルデンシュトレームマクログロブリン血症:最近のパイプライン動向

ワルデンシュトレームマクログロブリン血症:休止中のプロジェクト

ワルデンシュトレームマクログロブリン血症:開発が中止された製品

ワルデンシュトレームマクログロブリン血症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8527IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides an overview of the Waldenstrom Macroglobulinemia (Oncology) pipeline landscape.

Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Risk factors include age, gender, family history, Hepatitis C and certain types of autoimmune disease, such as Sjogren syndrome, might be at higher risk for WM. Treatment includes stem cell transplantation, biological therapy, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Waldenstrom Macroglobulinemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 10, 1 and 3 respectively for Waldenstrom Macroglobulinemia.

Waldenstrom Macroglobulinemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Waldenstrom Macroglobulinemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Waldenstrom Macroglobulinemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Waldenstrom Macroglobulinemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Waldenstrom Macroglobulinemia Overview
  • Therapeutics Development
    • Pipeline Products for Waldenstrom Macroglobulinemia - Overview
  • Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies
  • Waldenstrom Macroglobulinemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Waldenstrom Macroglobulinemia - Products under Development by Companies
  • Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Amgen Inc.
    • arGEN-X BV
    • Aurigene Discovery Technologies Limited
    • Bayer AG
    • BeiGene, Ltd.
    • Calithera Biosciences, Inc.
    • Celgene Corporation
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Hutchison MediPharma Limited
    • IGF Oncology, LLC.
    • Incyte Corporation
    • Juno Therapeutics Inc.
    • Karyopharm Therapeutics, Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Portola Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Vivolux AB
  • Waldenstrom Macroglobulinemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dezapelisib + itacitinib adipate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 765IGF-MTX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acalabrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-3111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bortezomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CA-4948 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-839 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dezapelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DI-B4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTRMWXHS-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entospletinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-523 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-50465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-7583 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4059 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oprozomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • spebrutinib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-659 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venetoclax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLX-1570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Waldenstrom Macroglobulinemia - Dormant Projects
  • Waldenstrom Macroglobulinemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Waldenstrom Macroglobulinemia - Dormant Projects, H2 2016
  • Waldenstrom Macroglobulinemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top